Suppr超能文献

真空辅助清除心脏装置相关感染性心内膜炎中的赘生物

Vacuum-Implemented Removal of Lead Vegetations in Cardiac Device-Related Infective Endocarditis.

作者信息

Tarzia Vincenzo, Ponzoni Matteo, Evangelista Giuseppe, Tessari Chiara, Bertaglia Emanuele, De Lazzari Manuel, Zanella Fabio, Pittarello Demetrio, Migliore Federico, Gerosa Gino

机构信息

Cardiac Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, 35128 Padua, Italy.

Cardiology Unit, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, 35128 Padua, Italy.

出版信息

J Clin Med. 2022 Aug 7;11(15):4600. doi: 10.3390/jcm11154600.

Abstract

When approaching infected lead removal in cardiac device-related infective endocarditis (CDRIE), a surgical consideration for large (>20 mm) vegetations is recommended. We report our experience with the removal of large CDRIE vegetations using the AngioVac system, as an alternative to conventional surgery. We retrospectively reviewed all infected lead extractions performed with a prior debulking using the AngioVac system, between October 2016 and April 2022 at our institution. A total of 13 patients presented a mean of 2(1) infected leads after a mean of 5.7(5.7) years from implantation (seven implantable cardioverter-defibrillators, four cardiac resynchronization therapy-defibrillators, and two pacemakers). The AngioVac system was used as a venous−venous bypass in six cases (46.2%), venous−venous ECMO-like circuit (with an oxygenator) in five (38.5%), and venous−arterial ECMO-like circuit in two cases (15.4%). Successful (>70%) aspiration of the vegetations was achieved in 12 patients (92.3%) and an intraoperative complication (cardiac perforation) only occurred in 1 case (7.7%). Subsequent lead extraction was successful in all cases, either manually (38.5%) or using mechanical tools (61.5%). The AngioVac system is a promising effective and safe option for large vegetation debulking in CDRIE. Planning the extracorporeal circuit design may represent the optimal strategy to enhance the tolerability of the procedure and minimize adverse events.

摘要

在处理心脏设备相关感染性心内膜炎(CDRIE)中的感染导线移除时,对于较大(>20 mm)赘生物,建议进行手术考量。我们报告了使用AngioVac系统移除大型CDRIE赘生物的经验,作为传统手术的替代方法。我们回顾性分析了2016年10月至2022年4月在我们机构使用AngioVac系统进行预先减容后进行的所有感染导线拔除病例。共有13例患者,植入后平均5.7(5.7)年出现平均2(1)根感染导线(7例植入式心律转复除颤器,4例心脏再同步化治疗除颤器,2例起搏器)。AngioVac系统在6例(46.2%)中用作静脉 - 静脉旁路,5例(38.5%)用作类似静脉 - 静脉体外膜肺氧合(ECMO)的回路(带有氧合器),2例(15.4%)用作类似静脉 - 动脉ECMO的回路。12例患者(92.3%)成功吸出(>70%)赘生物,仅1例(7.7%)发生术中并发症(心脏穿孔)。随后的导线拔除在所有病例中均成功,要么手动拔除(38.5%),要么使用机械工具拔除(61.5%)。AngioVac系统是CDRIE中大型赘生物减容的一种有前景的有效且安全的选择。规划体外循环设计可能是提高手术耐受性并将不良事件降至最低的最佳策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验